Redmile Group, LLC Kymera Therapeutics, Inc. Transaction History
Redmile Group, LLC
- $1.53 Billion
- Q2 2024
A detailed history of Redmile Group, LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 1,579,275 shares of KYMR stock, worth $71.7 Million. This represents 3.07% of its overall portfolio holdings.
Number of Shares
1,579,275
Previous 1,734,089
8.93%
Holding current value
$71.7 Million
Previous $69.7 Million
32.38%
% of portfolio
3.07%
Previous 2.75%
Shares
15 transactions
Others Institutions Holding KYMR
# of Institutions
160Shares Held
63.1MCall Options Held
22.6KPut Options Held
14.4K-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$290 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$272 Million2.38% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.35MShares$243 Million21.28% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$234 Million4.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$219 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.48B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...